Survival and multi-omics analysis of immunotherapy-based conversion treatment for initially unresectable gastric cancer

Song Li, Qian Xu, Wenbin Yu, Zimin Liu, Xiaohan Cui, Meng Wei, Duanbo Shi, Wen Zhao, Xinyu Song, Di Zhang, Zhaodi Nan, Ruibin Xi, Shuang Wang, Shulun Nie, Xin Dai, Lian LiuFrontiers in Immunology 2026 · DOI

This study, published in Frontiers in Immunology, explores a high-stakes frontier in oncology: using immunotherapy to turn "inoperable" gastric cancer into a treatable, surgically removable disease. By combining clinical outcomes with deep multi-omics sequencing, the researchers identify specific genetic signatures—specifically KMT2D mutations and Cytochrome P450 activity—that predict which patients will beat the odds.

TL;DR

Researchers demonstrated that immunotherapy-based "conversion therapy" can successfully enable radical surgery in over 80% of patients with initially unresectable gastric cancer, extending median survival to over 41 months. The study also identifies KMT2D mutations as a biomarker for treatment success and the Cytochrome P450 pathway as a key driver of drug resistance.

What Problem Does This Paper Address?

Gastric cancer (GC) is a leading cause of cancer-related death globally, often diagnosed only after it has become "unresectable"—meaning the tumor has invaded local structures or spread too far for surgery to be safe or effective. For these patients, the standard of care has traditionally been palliative, with a grim median survival of only 12 to 16 months.

While Immune Checkpoint Inhibitors (ICIs) have revolutionized treatment for advanced and resectable cases, their role in conversion therapy—treatment intended to shrink an unresectable tumor enough to allow for surgery—remains poorly defined. Furthermore, we lack a clear understanding of the molecular "why" behind patient response: why do some tumors melt away under immunotherapy while others remain stubbornly resistant?

Methods

The researchers conducted a retrospective cohort study of 73 patients with initially unresectable locally advanced or oligometastatic gastric cancer.

  • Treatment: Patients received a combination of ICIs (like PD-1 inhibitors) plus chemotherapy, sometimes supplemented with antiangiogenic agents.
  • Surgery: Following treatment, a multidisciplinary team (MDT) evaluated patients for surgical eligibility.
  • Multi-omics Analysis: This is the paper's technical core. The team performed:
  • Whole-Exome Sequencing (WES) and targeted sequencing on tumor biopsies to identify mutations.
  • RNA Sequencing to analyze gene expression and the tumor immune microenvironment (TIME).
  • Bioinformatics: They used tools like CIBERSORT and GSEA to map out immune cell infiltration and pathway activation.

Datasets

  • Qilu Cohort: The primary dataset of 73 patients from Qilu Hospital, Shandong University.
  • Qingdao Cohort: An independent validation set of 16 patients.
  • TCGA-STAD: The team utilized public data from The Cancer Genome Atlas (Stomach Adenocarcinoma) to validate their findings regarding immune cell correlations and the P450 signature.

Key Insights and Ideas

  • The "Hot" Mutation (KMT2D): The researchers found that mutations in the KMT2D gene were significantly associated with a Major Pathological Response (MPR). KMT2D mutations appear to "heat up" the tumor, increasing the infiltration of CD8+ T cells and Natural Killer (NK) cells, making the cancer more visible to the immune system.
  • The "Cold" Shield (P450 Signature): Conversely, tumors that resisted treatment showed high activity in the Cytochrome P450 pathway. This metabolic signature was linked to an "immunosuppressive" environment, characterized by more "pro-tumor" M2 macrophages and fewer "anti-tumor" effector cells.
  • R0 Resection is the Goal: The study confirms that achieving an R0 resection (complete removal of the tumor with no microscopic cancer cells at the margins) is the strongest predictor of survival. Patients who reached this milestone had an 80% reduction in the risk of death compared to those who didn't.
  • Pathological Response as a Proxy: Achieving a Pathological Complete Response (pCR)—where no viable tumor cells remain in the surgical specimen—correlated strongly with long-term survival, validating it as a critical endpoint for future trials.

Key Results

  • High Resection Rate: 82.2% of patients successfully underwent radical surgery (R0 resection) after conversion therapy.
  • Survival Boost: The median Overall Survival (OS) reached 41.3 months, a massive improvement over historical palliative benchmarks (~15 months).
  • Pathological Success: 24.7% of patients achieved a pCR, and 37.0% achieved an MPR.
  • Safety: Treatment-related adverse events were manageable, with only 16.4% of patients experiencing Grade 3 or higher side effects.

Limitations and Future Work

The authors acknowledge several limitations:

  1. Study Design: This was a retrospective, single-arm study. Without a randomized control group, it is difficult to definitively isolate the effect of the ICIs from the chemotherapy.
  2. Sample Size: While the clinical cohort was 73 patients, the multi-omics analysis was limited to smaller subsets (e.g., 27 for RNA-seq), which may limit the statistical power of the biomarker discovery.
  3. Selection Bias: As a real-world study, treatment regimens were not strictly standardized.

Future Directions: The team has already initiated a multicenter prospective study to validate these biomarkers. They also suggest that targeting the P450 pathway could be a novel strategy to overcome immunotherapy resistance in "cold" gastric tumors.

Summary updated

Abstract

ICIs-based conversion therapy demonstrates promising survival benefits and manageable safety profiles for patients with unresectable locally advanced or oligometastatic gastric cancer, and provides real-world evidence for a potential treatment strategy. Additionally, multi-omics findings have revealed drug resistance mechanisms and potential biomarkers of efficacy.
BibTeX
@inproceedings{li2026survival,
  author = {Song Li and Qian Xu and Wenbin Yu and Zimin Liu and Xiaohan Cui and Meng Wei and Duanbo Shi and Wen Zhao and Xinyu Song and Di Zhang and Zhaodi Nan and Ruibin Xi and Shuang Wang and Shulun Nie and Xin Dai and Lian Liu},
  title = {{Survival and multi-omics analysis of immunotherapy-based conversion treatment for initially unresectable gastric cancer}},
  booktitle = {Frontiers in Immunology},
  year = {2026},
  doi = {10.3389/fimmu.2025.1753749},
}
Figure